Search alternatives:
significant substantial » significant potential (Expand Search), significant spatial (Expand Search)
substantial decrease » substantial increase (Expand Search), substantially increased (Expand Search)
significant threat » significant effect (Expand Search), significant increase (Expand Search), significant decrease (Expand Search)
threat decrease » greater decrease (Expand Search), largest decrease (Expand Search)
Showing 141 - 160 results of 4,658 for search '(( significant substantial decrease ) OR ( significant threat decrease ))', query time: 0.33s Refine Results
  1. 141
    Annual Difference in Energy Consumption Relative to Historical Median Change by 2032.

    Annual Difference in Energy Consumption Relative to Historical Median Change by 2032. by Ryan P. Thombs (9138968)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  2. 142
    Coefficient plot of long-run effects.

    Coefficient plot of long-run effects. by Ryan P. Thombs (9138968)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 143
    Results for the asymmetric relationship between military expenditures and DOD energy consumption.

    Results for the asymmetric relationship between military expenditures and DOD energy consumption. by Ryan P. Thombs (9138968)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 144
    Time series of military expenditures and DOD energy consumption.

    Time series of military expenditures and DOD energy consumption. by Ryan P. Thombs (9138968)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 145
    Forecast for each scenario, 2023-2032.

    Forecast for each scenario, 2023-2032. by Ryan P. Thombs (9138968)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 146
    Trends in the days of third-generation cephalosporin therapy per 100 patients, by month, during Phases 1 to 4.

    Trends in the days of third-generation cephalosporin therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  7. 147
    Trends in the incidence of extended-spectrum β-lactamase (ESBL)- producing Enterobacteriaceae per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional period (Phases 2–4).

    Trends in the incidence of extended-spectrum β-lactamase (ESBL)- producing Enterobacteriaceae per 1000 patients, by month, during the pre-intervention period (Phase 1) and interven... by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  8. 148
    Trends in the incidence of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional period (Phases 2–4).

    Trends in the incidence of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional pe... by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  9. 149
    Trends in the days of sulfamethoxazole-trimethoprim therapy per 100 patients, by month, during Phases 1 to 4.

    Trends in the days of sulfamethoxazole-trimethoprim therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  10. 150
    Trends in the incidence of penicillin-resistant <i>Streptococcus pneumoniae</i> (PRSP) per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional period (Phases 2–4).

    Trends in the incidence of penicillin-resistant <i>Streptococcus pneumoniae</i> (PRSP) per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional... by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  11. 151
    Average purchase costs of 3GCs and all oral antimicrobials per 100 patient-days from Phases 1–4.

    Average purchase costs of 3GCs and all oral antimicrobials per 100 patient-days from Phases 1–4. by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  12. 152
    Trends in the incidence of resistant <i>Haemophilus influenzae</i> per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional period (Phases 2–4).

    Trends in the incidence of resistant <i>Haemophilus influenzae</i> per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional period (Phases 2–4).... by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  13. 153
    S1 Dataset -

    S1 Dataset - by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  14. 154
    Trends in the incidence of <i>Clostridioides difficile</i> infection (CDI) per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional period (Phases 2–4).

    Trends in the incidence of <i>Clostridioides difficile</i> infection (CDI) per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional period (Phas... by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  15. 155
    Trends in in-hospital mortality by month during the pre-intervention period (Phase 1) and interventional period (Phases 2–4).

    Trends in in-hospital mortality by month during the pre-intervention period (Phase 1) and interventional period (Phases 2–4). by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  16. 156
    Pop-up for oral 3GC prescription.

    Pop-up for oral 3GC prescription. by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  17. 157
    Trends in the days of cefalexin therapy per 100 patients, by month, during Phases 1 to 4.

    Trends in the days of cefalexin therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  18. 158
    Trends in the days of quinolone therapy per 100 patients, by month, during Phases 1 to 4.

    Trends in the days of quinolone therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  19. 159
    Trends in the length of hospital stay by month during the pre-intervention period (Phase 1) and interventional period (Phases 2–4).

    Trends in the length of hospital stay by month during the pre-intervention period (Phase 1) and interventional period (Phases 2–4). by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  20. 160
    Trends in the days of macrolides therapy per 100 patients, by month, during Phases 1 to 4.

    Trends in the days of macrolides therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:

Search Tools: